Antiphospholipid syndrome: Current insights into laboratory diagnosis and pathophysiology

Hamostaseologie

Volumn 30, Issue 3, 2010, Pages 139-143

  Van Os, G M A ^a,b   Urbanus, R T ^a   Agar, C ^b   Meijers, J C M ^b   De Groot, Ph G ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Antiphospholipid antibodies; Lupus anticoagulant

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; PHOSPHOLIPID ANTIBODY;

ANTIPHOSPHOLIPID SYNDROME; AUSTRALIA; CLINICAL PRACTICE; CONSENSUS DEVELOPMENT; DISEASE CLASSIFICATION; HUMAN; LABORATORY DIAGNOSIS; PATHOPHYSIOLOGY; REVIEW; ARTICLE; BLOOD; DIAGNOSIS, MEASUREMENT AND ANALYSIS; FEMALE; PHYSIOLOGY; PREGNANCY; PREGNANCY COMPLICATION;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; FEMALE; HUMANS; LABORATORY TECHNIQUES AND PROCEDURES; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 77956992874     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1619044     Document Type: Review

References (40)

1. Arnout J, Vermylen J. Current status and implications of autoimmune antiphospholipid antibodies in relation to thrombotic disease. J Thromb Haemost 2003; 1: 931-942.
2. Urbanus RT, Derksen RH, de Groot PG. Current insight into diagnostics and pathophysiology of the antiphospolipid syndrome. Blood Rev 2008; 22: 93-105.
3. Giannakopoulos B et al. How we diagnose the antiphospholipid syndrome. Blood 2009; 113: 985-994.
4. Wilson WA et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 1309-1311.
5. Miyakis S et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J.Thromb Haemost 2006; 4: 295-306.
6. Galli M et al. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003; 101: 1827-1832. (Pubitemid 36237580)
7. Wahl DG et al. Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis. Lupus 1998; 7: 15-22.
8. Kearon C et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic thromboembolism. New Engl J Med 1999; 340: 901-907. (Pubitemid 29141050)
9. Ginsberg JS et al. Antiphospholipid antibodies and venous thromboembolism. Blood 1995; 86: 3685-3691.
10. Urbanus RT et al. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurology 2009; 8: 998-1005.
11. Reber G, Boehlen F, de Moerloose P. Technical aspects in laboratory testing for antiphospholipid antibodies: is standardization an impossible dream? Semin Thromb Hemost 2008; 34: 340-346.
12. Reber G et al. Multicenter evaluation of nine commercial kits for the quantitation of anticardiolipin antibodies. The Working Group on Methodologies in Haemostasis from the GEHT (Groupe d'Etudes sur l'Hemostase et la Thrombose). Thromb Haemost 1995; 73: 444-452.
13. Jennings I et al. Lupus anticoagulant testing: improvements in performance in a UK NEQAS proficiency testing exercise after dissemination of national guidelines on laboratory methods. Br J Haematol 2002; 119: 364-369. (Pubitemid 35365483)
14. Galli M et al. Invitation to a debate on the serological criteria that define the antiphospholipid syndrome. J Thromb Haemostas 2008; 6: 399-401.
15. 2- glycoprotein I to phospholipids based on its crystal structure. EMBO Journal 1999; 18: 5166-5174.
16. Iverson GM et al. Use of single point mutations in domain I of beta 2-glycoprotein I to determine fine antigenic specificity of antiphospholipid autoantibodies. J Immunol 2002; 169: 7097-7103.
17. De Laat B et al. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of {beta}2-glycoprotein I cause LAC and their presence correlates strongly with thrombosis. Blood 2005; 105: 1540-1545. (Pubitemid 40223671)
18. Ioannou Y et al. Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: mutation studies including residues R39 to R43. Arthritis Rheum 2007; 56: 280-290
19. Ioannou Y et al. In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of beta2-glycoprotein I: proof of concept. J Thromb Haemost 2009; 7: 833-842.
20. Pengo V et al. Clinical course of high risk patients diagnosed with Antiphospholipid Syndrome (APS). J Thromb Haemost 2009; 7: 1737-1740.
21. 2-glycoprotein I - and prothrombin-dependent lupus anticoagulants. J Thromb Haemost 2003; 1: 740-747.
22. Oku K et al. Antiprothrombin antibody testing: detection and clinical utility. Semin Thromb Hemost 2008; 34: 335-339.
23. 2glycoprotein I. Proc Natl Acad Sci USA 1990; 87: 4120-4124.
24. Galli M et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma cofactor. Lancet 1990: 335: 1544-1547. (Pubitemid 20189625)
25. Hoeg JM et al. Characterization of plasma lipids and lipoproteins in patients with beta 2-glycoprotein I (apolipoprotein H) deficiency. The fasting plasma lipids, lipoproteins, and apolipoproteins were evaluated in 5 subjects. Atherosclerosis 1985; 55: 25-34.
26. Sheng et al. Impaired thrombin generation in beta 2-glycoprotein I null mice. J Biol Chem 2001; 276: 13817-13821.
27. Jankowski M et al. Thrombogenicity of beta 2-glycoprotein I-dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster. Blood 2003; 101: 157-162. (Pubitemid 36025902)
28. Shoenfeld Y, Blank M, Sherer Y. Induction and treatment of the antiphospholipid syndrome - lessons from animal models. Eur J Clin Invest 2001; 31: 736-740. (Pubitemid 32756623)
29. Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 2004; 10: 1222-1126. (Pubitemid 39540439)
30. Lozier J, Takahashi N, Putnam FW. Complete amino acid sequence of human plasma beta 2-glycoprotein I. Proc Natl Acad Sci USA 1984; 81: 3640-3644. (Pubitemid 14087780)
31. Ragusa MA et al. RT-PCR and in situ hybridization analysis of apolipoprotein H expression in rat normal tissues. Int J Mol Med 2006; 18: 449-455.
32. Agar C et al. Beta-glycoprotein I is incorrectly named apolipoprotein H. J Thromb Haemost 2009; 7: 235-236.
33. Palomo I et al. Antiphospholipid syndrome: a comprehensive review of a complex and multisystemic disease. Clin Exp Rheumatol 2009; 27: 668-677.
34. Satta N et al. The role of TLR2 in the inflammatory activation of mouse fibroblasts by human antiphospholipid antibodies. Blood 2007; 109: 1507-1514. (Pubitemid 46239583)
35. Pierangeli SS et al. Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies. Ann Rheum Dis 2007; 66: 1327-1333.
36. Romay-Penabad Z et al. C5a receptor-deficient mice are protected from thrombophilia and endothelial cell activation induced by some antiphospholipid antibodies. Ann NY Acad Sci 2007; 1108: 554-566. (Pubitemid 47528769)
37. Romay-Penabad Z et al. Annexin A2 is involved in antiphospholipid antibody-mediated pathogenic effects in vitro and in vivo. Blood 2009; 114: 3074-3083.
38. 2-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2′. J Biol Chem 2003; 278: 33831-33838
39. Romay-Penabad Z et al. Apolipoprotein E receptor 2′ mediates pathogenic effects of dimeric β2-glycoprotein I and anti-β2- glycoprotein I antibodies. Blood 2008; 112; 156
40. Pennings MT et al. Platelets express three different splice variants of ApoER2 that are all involved in signaling. J Thromb Haemost 2007; 5: 1538-1544.